LYRA THERAPEUTICS INC (LYRA)
US55234L1052 - Common Stock
Taking everything into account, LYRA scores 3 out of 10 in our fundamental rating. LYRA was compared to 193 industry peers in the Pharmaceuticals industry. LYRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LYRA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LYRA has reported negative net income.
LYRA had a negative operating cash flow in the past year.
LYRA had negative earnings in each of the past 5 years.
In the past 5 years LYRA always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -123.94%, LYRA is not doing good in the industry: 81.05% of the companies in the same industry are doing better.
With a Return On Equity value of -473.41%, LYRA is not doing good in the industry: 81.05% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -123.94% | ||
| ROE | -473.41% | ||
| ROIC | N/A |
ROA(3y)-57.82%
ROA(5y)-61.94%
ROE(3y)-88.45%
ROE(5y)-103.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LYRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYRA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LYRA has more shares outstanding
There is no outstanding debt for LYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
LYRA has an Altman-Z score of -9.08. This is a bad value and indicates that LYRA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LYRA (-9.08) is worse than 72.11% of its industry peers.
There is no outstanding debt for LYRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.08 |
ROIC/WACCN/A
WACC9.82%
2.3 Liquidity
LYRA has a Current Ratio of 3.64. This indicates that LYRA is financially healthy and has no problem in meeting its short term obligations.
LYRA's Current ratio of 3.64 is in line compared to the rest of the industry. LYRA outperforms 54.74% of its industry peers.
A Quick Ratio of 3.64 indicates that LYRA has no problem at all paying its short term obligations.
With a Quick ratio value of 3.64, LYRA perfoms like the industry average, outperforming 58.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
The earnings per share for LYRA have decreased by -5.67% in the last year.
LYRA shows a small growth in Revenue. In the last year, the Revenue has grown by 3.59%.
The Revenue has been growing slightly by 4.67% on average over the past years.
EPS 1Y (TTM)-5.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)3.59%
Revenue growth 3YN/A
Revenue growth 5Y4.67%
Sales Q2Q%-64.15%
3.2 Future
LYRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.73% yearly.
The Revenue is expected to grow by 84.26% on average over the next years. This is a very strong growth
EPS Next Y-9.83%
EPS Next 2Y21.56%
EPS Next 3Y12.15%
EPS Next 5Y12.73%
Revenue Next Year-12.34%
Revenue Next 2Y-32.82%
Revenue Next 3Y66.24%
Revenue Next 5Y84.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LYRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYRA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LYRA's earnings are expected to grow with 12.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.56%
EPS Next 3Y12.15%
5. Dividend
5.1 Amount
LYRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LYRA THERAPEUTICS INC
NASDAQ:LYRA (12/23/2024, 12:42:01 PM)
0.1717
-0.01 (-4.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners39.77%
Inst Owner Change-2.81%
Ins Owners0.65%
Ins Owner Change30.45%
Market Cap11.24M
Analysts74.55
Price Target1.27 (639.66%)
Short Float %4.24%
Short Ratio1.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.29%
Min EPS beat(2)-121.19%
Max EPS beat(2)22.6%
EPS beat(4)2
Avg EPS beat(4)-24.51%
Min EPS beat(4)-121.19%
Max EPS beat(4)31.53%
EPS beat(8)5
Avg EPS beat(8)-7.94%
EPS beat(12)7
Avg EPS beat(12)-4.5%
EPS beat(16)8
Avg EPS beat(16)-6.93%
Revenue beat(2)1
Avg Revenue beat(2)13.67%
Min Revenue beat(2)-40.26%
Max Revenue beat(2)67.6%
Revenue beat(4)2
Avg Revenue beat(4)-2.91%
Min Revenue beat(4)-63.18%
Max Revenue beat(4)67.6%
Revenue beat(8)5
Avg Revenue beat(8)39.86%
Revenue beat(12)6
Avg Revenue beat(12)22.91%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.37%
EPS NY rev (1m)-1.05%
EPS NY rev (3m)-1.05%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-42.68%
Revenue NY rev (1m)-12.78%
Revenue NY rev (3m)-12.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.55 | ||
| P/tB | 0.55 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.49
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.02
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -123.94% | ||
| ROE | -473.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-57.82%
ROA(5y)-61.94%
ROE(3y)-88.45%
ROE(5y)-103.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 780.15% | ||
| Cap/Sales | 216.38% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | -9.08 |
F-Score3
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)243.52%
Cap/Depr(5y)642.11%
Cap/Sales(3y)415.98%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-9.83%
EPS Next 2Y21.56%
EPS Next 3Y12.15%
EPS Next 5Y12.73%
Revenue 1Y (TTM)3.59%
Revenue growth 3YN/A
Revenue growth 5Y4.67%
Sales Q2Q%-64.15%
Revenue Next Year-12.34%
Revenue Next 2Y-32.82%
Revenue Next 3Y66.24%
Revenue Next 5Y84.26%
EBIT growth 1Y-7.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.77%
OCF growth 3YN/A
OCF growth 5YN/A